Clinical Trial Update: Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN [Phase 2]

View source ↗

Summary

Phase 2 trial assessing pegcetacoplan for post-transplant recurrence of C3 glomerulopathy and immune complex-mediated MPGN has completed with results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• C3 Glomerulopathy
• Dense Deposit Disease
• Immune Complex-mediated Membranoproliferative Glomerulonephritis
• Membranoproliferative Glomerulonephritis

Drugs mentioned

• Pegcetacoplan (Empaveli) (pegcetacoplan)

Snippet

Sponsor: Apellis Pharmaceuticals, Inc. | Conditions: C3G, IC-MPGN | Phase 2 | Status: COMPLETED | Results posted: 2025-02-07